Q1 updated the commercial trajectory relative to Q4’s outlook: Q4 guidance was "$825 million to $850 million" for 2026 U.S. BRIUMVI net revenue, while Q1 said, "we're raising full year U.S. revenue ...
TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results